Methadone Medical Maintenance

Policy Statement

Number 1

April 1994

The National Alliance of Methadone Advocates supports the concept of Medical Maintenance and the prescribing of methadone outside of the methadone clinic setting. Medical Maintenance was initially implemented for patients who had achieved a high level of functionally in society and were hindered by the regulations that were conceived with the dysfunctional patient in mind. Another concern by the designers of Medical Maintenance was the stigma associated with methadone maintenance. The prejudice and misunderstanding of methadone maintenance places the stabilized and fully rehabilitated patient at risk of losing everything they have accomplished if they are seen entering a methadone program. Medical Maintenance can also provide treatment for patients who would not respond well in the program setting and may need specialized treatment that a physician can offer.

Methadone maintenance should be designed to meet the needs of all patients, unfortunately it does not. Medical Maintenance will begin to address these problems. The epidemic of HIV among intravenous drug users creates an urgency to redesign the methadone system to reach all those at risk. At the very least Medical Maintenance will free the fully rehabilitated patient thus opening additional treatment places for those who desperately need methadone treatment.

Since its beginning methadone maintenance has been the most popular treatment for narcotic addiction. Many times over the years methadone treatment had been demonstrated to be the most effective treatment for narcotic addiction, resulting the termination of heroin use and of criminal behavior. In spite of its success, methadone maintenance is often disparaged as a “substitute drug” by those who ignore the positive benefits that it had clearly brought to society. These attitudes negatively impact on methadone maintenance programs in a variety of ways, but it is the methadone patients themselves who are particularly stigmatized and harmed. The atmosphere will not change as long as there is no organization or formal mechanism for methadone patients to voice their own needs and to form a strong unified public presence on their own behalf. As the premier national advocacy organization for methadone treatment the National Alliance of Methadone Advocates, Inc. (NAMA) will actively respond to the issues that affect the daily lives of methadone patients and work towards the day when all methadone patients can take pride in their accomplishments.

[Download PDF] 

[Next Policy Statement]

[Index Policy Statements]

Similar Posts

  • Federal Regulations & Accreditation Resources

    Admin 08/24/2021

    Federal Regulations & Documents Code of Federal Regulations. Opioid Drugs in Maintenance and Detoxification Treatment of Opiate Addiction; Final Rule 21 CRF 291, 42 CRF 8. (Text) Federal Regulations (PDF Format) . Code of Federal Regulations. Confidentiality of Alcohol and Drug Abuse Patient Records (PDF Format). CSAT Accreditation Page. CSAT Guidelines for the accreditation of…

  • Page 4098 Federal Register

    Admin 08/28/2021

     Vol. 66, No. 11 / Wednesday, January 17, 2001 / Rules and Regulations (i)                 Unsupervised or take-home use.   To limit the potential for diversion of opioid agonist treatment medications to the illicit market, opioid agonist treatment medications dispensed to patients for unsupervised use shall be subject to the following requirements.   (1)   Any patient…

  • Basic Information for Patients About Buprenorphine

    Admin 11/29/2021

    Basic Information About Buprenorphine Federal Law For the first time in nearly a century physicians may now treat opiate addiction. On October 17, 2000 Title XXXV of the Children’s Health Act of 2000 was enacted that permits the prescribing of certain medications to treat opiate addiction. Physicians may now prescribe Schedule III, IV, and V…

  • Orlaam(LAAM) Alert

    Admin 06/17/2021

    FDA Warns About Orlaam T01-15 Print Media: 301-827-6242 April 20, 2001 Broadcast Media: 301-827-3434   Consumer Inquiries: 888-INFO-FDA The U.S. Food and Drug Administration (FDA) issued a new warning about health risks associated with levomethadyl acetate HC, a.k.a. Orlaam, a drug used to treat opiate addiction. FDA Announces Labeling Changes Following Cardiac Adverse Events With…

  • Methadone Maintenance and Patient Self-Advocacy by Arlene S. Ford

    Admin 06/19/2022

    Education Series Number 1 March 1991 Arlene Ford helped to start one of the first methadone advocacy groups at Nassau County Medical Center. This article was written for the COMPA Newsletter for distribution at the National Methadone Conference. Methadone has allowed me to salvage my life. In May of 1988, following a fourth relapse, my…

  • Archives

    Admin 05/05/2022

    2003 Connolly, James. Methadone Saves Lives (Letter). Scranton Times Tribune (01/08/2003). (Pennsylvania NAMA) Faces and Voices of Recovery. Brief Summary of the Addiction is NOT Fashionable Camapign. International protest against Dior Addict products and marketing, January 15, 2003. City of Detroit Resolution. National Alliance of Methadone Advocates. Letter to the Governor, Oregon January 17, 2003….